Charles River Labs Stock - Morgan Stanley upgrade highlights biopharma tailwind

Edited by ad hoc news Analyst & Consensus Desk. Verified prior to publication on 06/21/2026, 12:06 CET. Details in the imprint.

Charles River Labs (US1591881009) sits in the analyst spotlight after a notable call from Morgan Stanley. The US broker recently upgraded the stock from Equal Weight to Overweight, citing improving biopharma funding and stronger demand for preclinical research services.

Morgan Stanley changes its view

Morgan Stanley has shifted its stance on Charles River Labs to Overweight from Equal Weight, signaling a more constructive view on the contract research group’s medium-term prospects. The bank points to recovering biopharma funding as a key driver for new requests for proposals and bookings.

According to the analyst note summarized in financial news reports, the house expects increased outsourcing of preclinical work as biotech and pharma clients refocus on pipeline progress. That trend would support utilization across Charles River’s discovery and safety assessment businesses.

How the broader analyst consensus looks

The Morgan Stanley call adds to an already mixed but generally positive analyst backdrop for Charles River Labs. Data from major financial portals shows a blend of Buy and Hold ratings, with only a small minority on the Sell side.

Consensus estimates for the current fiscal year still assume low- to mid-single-digit revenue growth, reflecting lingering caution after a softer funding environment in 2023. At the same time, margin expectations suggest analysts see room for gradual profitability improvement as volume returns to higher-margin segments.

What the company sells

Charles River Labs generates most of its revenue as a contract research organization supporting drug discovery and development. The group provides preclinical safety assessment, discovery services and also supplies research models such as laboratory animals and associated services to pharma and biotech clients.

Where the stock trades today

Charles River Labs shares (US1591881009) trade on the New York Stock Exchange at $248.30 as of 06/21/2026, 11:45 ET.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.